Literature DB >> 29618498

Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study.

Carl Eriksson1, Sara Rundquist1, Yang Cao2,3, Scott Montgomery2,4,5, Jonas Halfvarson1.   

Abstract

OBJECTIVE: Thiopurines are used as maintenance therapy in ulcerative colitis (UC), but whether these drugs influence the natural history of the disease is unknown. We aimed to assess the effect of thiopurines in terms of colectomy, hospital admission, progression in disease extent and anti-tumour necrosis factor (TNF) therapy within 10 years from initiation.
DESIGN: Patients diagnosed with UC within the Örebro University Hospital catchment area, during 1963-2010, who initiated thiopurines (n=253) were included. To overcome the risk of confounding by indication, we compared patients who stopped treatment within 12 months because of an adverse reaction (n=76) with patients who continued therapy or discontinued due to other reasons (n=177) and assessed long-term outcomes using Cox regression with adjustment for potential confounding factors.
RESULTS: The cumulative probability of colectomy within 10 years was 19.5% in tolerant patients compared with 29.0% in intolerant (adjusted HR 0.49; 95% CI 0.21 to 0.73). The probability of hospital admission was 34.0% in tolerant versus 56.2% in intolerant patients (adjusted HR 0.36; 95% CI 0.23 to 0.56). The risk for progression in disease extent was 20.4% in tolerant patients compared with 48.8% in intolerant (adjusted HR 0.47; 95% CI 0.21 to 1.06). Within 10 years, 16.1% of tolerant and 27.5% of intolerant patients received anti-TNF therapy (adjusted HR 0.49; 95% CI 0.26 to 0.92).
CONCLUSION: Based on the novel approach of comparing patients tolerant and intolerant to thiopurines, we reveal that thiopurines have a profound beneficial impact of the natural history and long-term colectomy rates of UC. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  6-mercaptopurine; azathioprine; chronic ulcerative colitis; tnf-alpha

Mesh:

Substances:

Year:  2018        PMID: 29618498     DOI: 10.1136/gutjnl-2017-315521

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  6 in total

Review 1.  An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.

Authors:  Francesca Ferretti; Rosanna Cannatelli; Maria Camilla Monico; Giovanni Maconi; Sandro Ardizzone
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

Review 2.  The Evolving Role of Thiopurines in Inflammatory Bowel Disease.

Authors:  Saurabh Kapur; Stephen B Hanauer
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

Review 3.  Recent advances and emerging therapies in the non-surgical management of ulcerative colitis.

Authors:  Jan Wehkamp; Eduard F Stange
Journal:  F1000Res       Date:  2018-08-07

Review 4.  The Evolving Role of Thiopurines in Inflammatory Bowel Disease.

Authors:  Saurabh Kapur; Stephen B Hanauer
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

5.  Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.

Authors:  Evangelos Stournaras; Wendi Qian; Tim Raine; Miles Parkes; Apostolos Pappas; You Yi Hong; Rasha Shawky
Journal:  Gut       Date:  2020-10-01       Impact factor: 23.059

6.  Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018.

Authors:  Satimai Aniwan; Julajak Limsrivilai; Supot Pongprasobchai; Nonthalee Pausawasdi; Piyapan Prueksapanich; Natanong Kongtub; Rungsun Rerknimitr
Journal:  Intest Res       Date:  2020-08-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.